Last reviewed · How we verify
Timolol Vehicle (placebo)
This is a placebo vehicle formulation with no active pharmacological mechanism.
This is a placebo vehicle formulation with no active pharmacological mechanism. Used for Placebo control in clinical trials for glaucoma and ocular hypertension.
At a glance
| Generic name | Timolol Vehicle (placebo) |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol Vehicle is the inactive carrier solution used in ophthalmic formulations of timolol, designed to match the physical and chemical properties of the active drug product without containing the beta-blocker itself. It serves as a control comparator in clinical trials to isolate the therapeutic effects of timolol from vehicle-related effects.
Approved indications
- Placebo control in clinical trials for glaucoma and ocular hypertension
Common side effects
Key clinical trials
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension (PHASE3)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension (PHASE2)
- Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE4)
- Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma (PHASE1)
- Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (PHASE1, PHASE2)
- Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timolol Vehicle (placebo) CI brief — competitive landscape report
- Timolol Vehicle (placebo) updates RSS · CI watch RSS
- Allergan portfolio CI